Summary of the National Advisory Committee on Immunization (NACI) Statement Update on the Recommended Use of Hepatitis A Vaccine.
Background The severity of hepatitis A (HA) increases with age. Children less than six years of age are commonly asymptomatic or present with mild disease without jaundice and represent an important source of infection, particularly for household members and other close contacts. In older children and adults, HA is typically symptomatic. Older persons and individuals with chronic liver disease and immunocompromising conditions have an increased risk of progressing to fulminant hepatic failure resulting in death. Immunization with HA vaccine is recommended for pre exposure immunization of persons at increased risk of infection or severe HA, as well as within 14 days of HA exposure for: susceptible household and close contacts of proven or suspected cases of HA; co workers and clients of infected food handlers; and staff and attendees of group child care centres and kindergartens where HA has occurred. Canada's National Advisory Committee on Immunization (NACI) has previously recommended HA vaccination for persons one year of age and over. Objectives To make recommendations for the use of HA vaccine in infants less than one year of age and to clarify recommendations for the post exposure use of human immune globulin (Ig) Methods The NACI Hepatitis Working Group (HWG) performed literature reviews and reviewed vaccine manufacturer provided data on the topic of HA post exposure prophylaxis. All evidence was rated and reported in evidence tables. A knowledge synthesis was performed and NACI approved specific evidence based recommendations, elucidating the rationale and relevant considerations. Results No studies on the efficacy or effectiveness of HA containing vaccines in children six to less than 12 months of age were identified through the literature search. Receipt of two doses of HA containing vaccines was found to be safe and immunogenic in infants six to 12 months of age. Limited data were available regarding HA containing vaccine immunogenicity in adults over the age of 40 years. Conclusion There are now new NACI recommendations on HA vaccine and post exposure use of Ig.
Canada communicable disease report Releve des maladies transmissibles au Canada